Evidence map›Paper›PMID 37358329›Full record

ArticleACS applied materials & interfaces2023

High Recognition of Isomer-Stabilized Gold Nanoparticles through Matrix Imprinting.

Din Zelikovich, Pavel Savchenko, Daniel Mandler

Open access · hybridAbstract read
In one paragraph

Article in ACS applied materials & interfaces, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Din ZelikovichInstitute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel.
Pavel SavchenkoInstitute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel.
Daniel MandlerInstitute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel.ORCID 0000-0003-2490-1084
Hebrew University of Jerusalem · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of highly selective probes for nanoparticles is required due to their nanotoxicity. The latter strongly depends on the size, structure, and interfacial properties of the nanoparticles. Here, we demonstrate that a simple approach for the selective detection of Au nanoparticles that differ in their capping agent shows very high promise. Specifically, gold nanoparticles stabilized by each of the three different isomers of mercaptobenzoic acid (MBA) were imprinted in a soft matrix by adsorption of the nanoparticles, followed by filling the non-occupied areas through electropolyermization of an aryl diazonium salt (ADS). Nanocavities bearing the shape of the Au nanoparticles were formed upon the electrochemical dissolution of the nanoparticles, which were used for the reuptake of the Au nanoparticles stabilized by the different isomers. High reuptake selectivity was found where the originally imprinted nanoparticles were recognized better than the Au nanoparticles stabilized by other MBA isomers. Furthermore, an imprinted matrix by nanoparticles stabilized by 4-MBA could also recognize nanoparticles stabilized by 2-MBA, and vice versa. A detailed study using Raman spectroscopy and electrochemistry disclosed the organization of the capping isomers on the nanoparticles as well as the specific nanoparticle-matrix interactions that were responsible for the high reuptake selectivity observed. Specifically, the Raman band at ca. 910 cm

Indexed as

gold nanoparticlesimprintingnanoparticles detectionnanoparticles imprinted matrices (NAIM)Raman spectroscopy

Identifiers

PMID37358329
PMCPMC10347121
OpenAlexW4382010621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.